Cite

    Roberto Ravasio et al.. “Cost per responder for ixekizumab and other biologic drugs approved for the treatment of moderate-to-severe plaque psoriasis in Italy.” Global & regional health technology assessment, vol. 2019, 2019, p. . http://access.bl.uk/ark:/81055/vdc_100091634779.0x000003